PCSK9 and familial hypercholesterolemia: Particularly, the availability of PCSK9 inhibitors has dramatically reduced the number of patients requiring apheresis for elevated LDL-cholesterol, as patients with familial hypercholesterolemia usually respond well to PCSK9 inhibitor therapy and the majority of patients with statin intolerance tolerate PCSK9 inhibitors well [6].